Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension.

[1]  R. Allman,et al.  Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. , 2021, The American journal of medicine.

[2]  Douglas F. Redd,et al.  Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[3]  G. Fonarow,et al.  Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. , 2020, The American journal of medicine.

[4]  Deepak L. Bhatt,et al.  Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. , 2020, The American journal of medicine.

[5]  G. Fonarow,et al.  Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. , 2020, Journal of the American College of Cardiology.

[6]  G. Fonarow,et al.  Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrillation. , 2020, The American journal of medicine.

[7]  G. Fonarow,et al.  Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. , 2020, The American journal of medicine.

[8]  S. Solomon,et al.  Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. , 2020, Journal of the American College of Cardiology.

[9]  C. Morgan,et al.  Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[10]  S. Yusuf,et al.  Digoxin–mortality: randomized vs. observational comparison in the DIG trial , 2019, European heart journal.

[11]  C. Morgan,et al.  Prior Heart Failure Hospitalization and Outcomes in Patients with Heart Failure with Preserved and Reduced Ejection Fraction. , 2019, The American journal of medicine.

[12]  C. Yancy,et al.  Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction , 2018, JAMA cardiology.

[13]  Akshay S. Desai,et al.  Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial , 2018, European journal of heart failure.

[14]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[15]  F. Messerli,et al.  Observations on the blood pressure paradox in heart failure , 2017, European journal of heart failure.

[16]  S. Solomon,et al.  Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.

[17]  R. Lewis,et al.  Confounding by Indication in Clinical Research. , 2016, JAMA.

[18]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[19]  R. Allman,et al.  Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. , 2013, International journal of cardiology.

[20]  M. Hernán,et al.  Systematic Reviews and Meta-and Pooled Analyses Bias in Observational Studies of Prevalent Users : Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins , 2012 .

[21]  C. Wanner,et al.  Reverse Epidemiology in Systolic and Nonsystolic Heart Failure: Cumulative Prognostic Benefit of Classical Cardiovascular Risk Factors , 2009, Circulation. Heart failure.

[22]  R. Allman,et al.  Isolated Systolic Hypertension and Incident Heart Failure in Older Adults: A Propensity-Matched Study , 2009, Hypertension.

[23]  E. Ferenczi,et al.  Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure , 2008, Heart.

[24]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[25]  Kamyar Kalantar-Zadeh,et al.  Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[26]  D. Rubin.  Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.

[27]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[28]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .